Dr Reddy’s Laboratories has received final approval for its Abbreviated New Drug Application (ANDA) Fondaparinux Sodium Injection, a bioequivalent generic version of Arixtra from the United States Food and Drug Administration (USFDA) in collaboration with Alchemia, Brisben, Australia.
The approval covers 2.5mg/ 0.5mg/ 0.4ml, 7.5mg/0.6ml and 10mg/0.8ml doses of the drug in prefilled color-coded, single-dose syringes with automatic needle safety device. The company will manufacture fondaparinux under license using a patented process developed by Alchemia.
The company’s net profit for the fourth quarter declined by 34.48% at Rs 165.87 crore as compared to Rs 253.16 crore for the corresponding quarter previous year. Its total income increased by 7.11% at Rs 1375.77 crore for the quarter under review from Rs 1284.43 crore in the corresponding previous quarter.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1669.50 |
| Dr. Reddys Lab | 1216.60 |
| Cipla | 1235.00 |
| Zydus Lifesciences | 928.00 |
| Lupin | 2300.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: